Logo

Prices of more than 5,400 medications to become cheaper in April

Prices of more than 5,400 medications to become cheaper in April

2023-03-03

Recently, the National Health Insurance Administration announced that more than 5,400 medications will become cheaper in April. The biggest price drop will be for Ebixa, a brand-name drug used to treat Alzheimer’s disease. With a price cut of 30%, reports have emerged that the drug’s manufacturer may pull out of Taiwan. The NHIA on Friday clarified that the medication would still be available in Taiwan, adding that other pharma companies are producing identical medication, although it wouldn’t be with the moniker Ebixa.

These medicines on the counter include several treatments to lower blood pressure. They are all in a NHIA list of 5,000 medicines that will soon have lower prices. The biggest price drop will be for heart medications, which will see prices fall by about 9%. The second biggest cut is for medicines for the nervous system.

Shen Tsai-ying
Pharmacist
They have their value, and many patients take these medicines. If you cut their prices and they stop getting produced, you’d end up having to switch to a more expensive drug. And that would not save the NHI system any money.

One of the medications set to become cheaper is this medication for Alzheimer’s disease: Ebixa film-coated tablets, which are produced by a Danish company. Their price will go down from NT$8.9 per tablet to NT$6.3, a drop of nearly 30% and the biggest cut of all. Reports say the manufacturer has threatened to pull out of the Taiwan market due to the price drop.

Voice of Chen Jui-hsing
Far Eastern Memorial Hospital
Patients with moderate to severe symptoms all take Ebixa. There is no way to tell how well the Taiwan-made drugs will do, because there is no way to do an assessment.

Hung Tzu-jen
Shin Kong Wu Ho Su Memorial Hospital
The manufacturer may think that the cost of production will be higher than the price after the cut. I suggest that they provide a cost analysis to the NHIA to reverse the decision.

The NHIA says Ebixa has been offered in the system for more than 15 years, and its patent has already expired. That’s why its price will be lowered to match the price of generics with the same ingredients, quantity and format.

Voice of Huang Yu-wen
National Health Immigration Agency
Ebixa will stay. And there are medicines from five other makers with stable production.

Ebixa’s agent in Taiwan for its part says it will discuss the matter with the NHIA.

砍阿茲海默藥價"傳藥廠退出台灣" 健保署急澄清

2023-03-03

健保署日前公布調整藥價給付,超過5400項調降,其中被砍最多的是治療阿茲海默症的"憶必佳膜衣錠",降幅近三成,傳出藥廠揚言退出台灣。不過健保署澄清,憶必佳會續留在台灣,還有其他五個品牌產能穩定,不會影響臨床用藥。

藥品一字排開,包含不少降血壓藥,都在健保署的價格調整名單中,這次共調降5千多項藥品,心臟血管用藥降幅最多,近9%,其次是神經系統用藥。

[[藥師 沈采穎]]
“它有它存在的價值,而且是有蠻多病人在吃。你把它砍,其實有時候要換比較高價的藥,去替代這個廉價的藥,健保支出其實並沒有節省。”

砍價名單中,用於治療阿茲海默症的一款丹麥原廠藥"憶必佳膜衣錠",最受關注。從一顆要價8.9元,降為6.3元,降幅近三成,砍價最多,傳出藥廠不滿砍價,揚言退出台灣市場。

[[聲源:亞東醫院失智中心主任 甄瑞興]]
“病人只要是中重度都會使用憶必佳。用台廠藥效果怎麼樣無法得知,因為你沒辦法去評估它。”

[[新光醫院副院長 洪子仁]]
“藥廠覺得是說它的生產成本,事實上已經高出來這次降下來藥價。我建議能夠提出它的成本架構,以及它的成本分析表,向健保來作申覆。”

不過健保署也說明,因為憶必佳收在健保,已經超過十五年而且過了專利期,加上有學名藥可取代,才把同成分、含量、劑型的藥物調成相同價格。

[[聲源:健保署醫審及藥材組長 黃育文]]
“憶必佳它會繼續留下來,還有5款品牌其實產能也都很穩定。”

憶必佳的台灣代理商則表示,會和健保署申請重新核價。

Related News

Arms deal of US$619 million in line with American government policy: US official

2023-03-03

Controversy erupts over proposed revisions to national mobilization act

2023-03-03

Employee tensions over management culture at TSMC US fab: New York Times report

2023-03-03

Dentist moves to seaside town in Taitung for love, in real-life version of a rom-com

2023-03-03

December, January and February were coldest three months in five years: meteorologist

2023-03-03